DOCSLIB.ORG

CYP2C9 and VKORC1 Testing for Warfarin Response

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CYP2C9 and VKORC1 Testing for Warfarin Response Lab Management Guidelines v2.0.2019 CYP2C9, VKORC1, and CYP4F2 Testing for Warfarin Response MOL.TS.156.A v2.0.2019 Procedures addressed The inclusion of any procedure code in this table does not imply that the code is under management or requires prior authorization. Refer to the specific Health Plan's procedure code list for management requirements. Procedures addressed by this Procedure codes guideline CYP2C9 Genotyping 81227 VKORC1 Genotyping 81355 CYP4F2 Genotyping 81479 Warfarin responsiveness testing by G9143 genetic technique using any method What is Warfarin sensitivity testing? Definition Warfarin (Coumadin® ) is a commonly prescribed anticoagulant with a narrow therapeutic range and a 20-fold inter-individual variation in dose requirements.1 Incorrect dosage, especially during the initial dosing phase, is associated with either severe bleeding or failure to prevent thromboembolism.2 Approximately 21% of patients who receive anticoagulant therapy will experience a major or minor bleeding event.2 Environmental and genetic factors combined influence 55% of warfarin dose variability and include: age, height, body mass index (BMI), gender, diet, genetic variations in CYP2C9 and VKORC1, use of concomitant medications and indication for warfarin.3,4 The activity of two genes [cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit-1 (VKORC1)] impact the rate of warfarin metabolism and account for up to 40% of the inter-individual dose requirements for warfarin.4 The addition of a third gene, cytochrome P450 4F2 (CYP4F2) accounts for an additional 2% of warfarin dosing variability.5 CYP2C9 is a p450 enzyme that influences warfarin pharmacokinetics by impacting the rate of metabolism. Poor or intermediate metabolizing 2C9 variants are seen in between 2% to 20% of the population depending on ethnicity.2 Carriers of alleles *2 and *3 have decreased warfarin metabolism and may require lower warfarin doses.4 © eviCore healthcare. All Rights Reserved. 1 of 5 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com Lab Management Guidelines v2.0.2019 Vitamin K activity is important to the blood’s ability to clot. VKORC1 influences the pharmacodynamics and sensitivity of warfarin on the vitamin K cycle. Approximately 14% to 89% of the population display VKORC1 enzyme inhibition making them more sensitive to warfarin.2 Carriers of VKORC1 AA genotype (high warfarin sensitivity) require a significantly lower warfarin dose compared to individuals with genotype GA or GG.4 CYP4F2 is a p450 enzyme that counteracts the effects of VKORC1 by limiting the excessive accumulation of Vitamin K. Depending on ethnicity, carriers of the *3 allele (AA or GA genotypes) have a moderate 8-11% increase in warfarin dosing requirements compared to individuals with genotype GG. 5,9 Testing these three genes predicts variability in warfarin dosage requirements. The presence of gene variants in CYP2C9, VKORC1, and CYP4F2 indicate that more careful dosing and monitoring is required to achieve therapeutic anticoagulation and to decrease risk of bleeding or clotting during warfarin dose titration. Test information The CYP2C9 allele is thought to be the predominant cause of the variation of warfarin dosing.6 n There are approximately 37 alleles reported in the CYP complex, however many do i r not have a functional impact. a f o Two alleles, *2 and *3 (CYP2C9*2 and CYP2C9*3) are linked to a slower r metabolism of warfarin, thereby needing an increase in warfarin dose. These a alleles are found in approximately 12.2% and 7.9%, respectively, of the 7 W European Caucasian population. - o Other variants, *4, *5, and *6 are seen in the Asian and African American populations, but typically around a <1% incidence.8 1 C Diagnosis of these alleles can occur through sequence analysis of the CYP2C9, R VKORC1, and CYP4F2 genes. Mutation analysis detects virtually 100% of alleles.2,5 O K V Guidelines and evidence There has been a mixed response to genotyping from professional associations, d payors, and other organizations, largely because data supporting the utility of n a genetic testing to improve clinical endpoints is conflicting. For example, two recent meta-analyses came to opposite conclusions: 9 o A genotype-guided dosing strategy did not result in a greater percentage of time C that the INR was within the therapeutic range, fewer patients with an INR 2 greater than 4, or a reduction in major bleeding or thromboembolic events P 6 compared with clinical dosing algorithms. Y C © eviCore healthcare. All Rights Reserved. 2 of 5 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com Lab Management Guidelines v2.0.2019 o Genotype-guided initial dosing is able to reduce serious bleeding events by approximately 50% (RR = 0.47; 95% CI, 0.23-0.96; P = 0.040) compared with clinically-guided dosing approaches.8 The Clinical Pharmacogenetics Implementation Consortium (CPIC, 2017) guidelines state “This guideline recommends that pharmacogenetic warfarin dosing be accomplished through the use of one of the pharmacogenetic dosing algorithms…The two algorithms provide very similar dose recommendations...The warfarindosing.org website contains both algorithms, the Gage algorithm as the primary algorithm and the IWPC [International Warfarin Pharmacogenetics Consortium] algorithm as the secondary algorithm…” It also notes “In patients of African ancestry, CYP2C9*5, *6, *8, *11 are important for warfarin dosing. If these genotypes are not available, warfarin should be dosed clinically without consideration for genotype.” 9 In January 2015, the American Heart Association published a Scientific Statement on Basic Concepts and Potential Applications of Genetics and Genomics for Cardiovascular and Stroke Clinicians.10 They noted: o “No cardiovascular pharmacogenetic application has yet been fully validated or widely adopted.” o “Building on these early findings, additional clinical studies of warfarin n pharmacogenetics are underway.” i r a The American College of Medical Genetics (ACMG, 2008) and the American f College of Chest Physicians (ACCP, 2008) both suggest against routine genotyping r to guide warfarin dosing until better evidence is available to support a policy a decision, but the ACMG does say that testing might be useful to explain unexpected W warfarin responses.7,11 - An FDA Advisory Committee convened in November of 2005 voted unanimously 1 that “sufficient mechanistic and clinical evidence exists to support the recommendation to use lower doses of warfarin for individuals with genetic C variations in CYP2C9 and VKORC1 that lead to reduced activities.” Furthermore, R their report states “genotyping people in the induction phase of warfarin therapy O would reduce adverse events and improve achievement” of a stable dose for K anticoagulation.9 Product labeling for Coumadin (warfarin) has been updated based V on FDA recommendation to include a table recommending initial dosing ranges for patients with different combinations of CYP2C9 and VKORC1 genotypes. Labeling d also includes the range of expected therapeutic warfarin doses based on CYP2C9 n 4 and VKORC1 genotypes. a Publications based on the European Pharmacogenetics of Anticoagulant Therapy 9 (EU-PACT) trial data have indicated that pharmacogenomics-driven dosing C algorithms may need to be age- and ethnicity-specific. This revised approach to 2 dosing algorithms will need additional research and validation.12,13 P Y C © eviCore healthcare. All Rights Reserved. 3 of 5 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com Lab Management Guidelines v2.0.2019 Criteria This test is considered investigational and/or experimental. Investigational and experimental (I&E) molecular and genomic (MolGen) tests refer to assays involving chromosomes, DNA, RNA, or gene products that have insufficient data to determine the net health impact, which typically means there is insufficient data to support that a test accurately assesses the outcome of interest (analytical and clinical validity), significantly improves health outcomes (clinical utility), and/or performs better than an existing standard of care medical management option. Such tests are also not generally accepted as standard of care in the evaluation or management of a particular condition. In the case of MolGen testing, FDA clearance is not a reliable standard given the number of laboratory developed tests that currently fall outside of FDA oversight and FDA clearance often does not assess clinical utility. References 1. Kangelaris KD, Bent S, Nussbaum RL.Genetic Testing Before Anticoagulation? A Systematic Review of Pharmacogenetic Dosing of Warfarin. J Gen Intern Med. 2009 May;24(5):656-64. n i 2. American Medical Association (AMA) Molecular medicine. Brochure: Personalized r Healthcare Report 2008: Warfarin and genetic testing. a f 3. Kamali F. Genetic influences on the response to warfarin. Curr Opin Hematol. r 2006;13(5):357-361. a 4. U.S. Food and Drug Administration. Coumadin Labeling. Updated January 22, W 2010. Available at: - http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/009218s108lbl.pdf. 1 5. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required C warfarin dose. Blood. 2008 Apr 15;111(8):4106–4112. R 6. Stergiopoulos K, Brown DL. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. JAMA Intern Med. O 2014;174(8):1330-8. K V 7. Flockhart DA, O'Kane D, Williams MS, et al; ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use. d Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet n Med. 2008 Feb;10(2):139-50. a 8. Franchini M, Mengoli C, Cruciani M, et al. Effects on bleeding complications of 9 pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic C review and meta-analysis. J Thromb Haemost. 2014;12(9):1480-7. 2 9. Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation P Consortium (CPIC) Guideline for pharmacogenetics-guided warfarin dosing: 2017 Y C © eviCore healthcare.
Load more

Recommended publications
  • Association of VKORC1 and CYP2C9 Polymorphisms with Warfarin Dose Requirements in Japanese Patients
    J Hum Genet (2006) 51:249–253 DOI 10.1007/s10038-005-0354-5 ORIGINAL ARTICLE Taisei Mushiroda Æ Yozo Ohnishi Æ Susumu Saito Atsushi Takahashi Æ Yuka Kikuchi Æ Shigeru Saito Hideki Shimomura Æ Yasuhiko Wanibuchi Takao Suzuki Æ Naoyuki Kamatani Æ Yusuke Nakamura Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients Received: 11 October 2005 / Accepted: 28 November 2005 / Published online: 24 January 2006 Ó The Japan Society of Human Genetics and Springer-Verlag 2006 Abstract Warfarin is the most commonly used oral homozygous for the major allele (2.5 mg/day; anticoagulant for treatment of thromboembolism, but P=5.1·10À11 in the case of intron 1À136T>C SNP). adjustment of the dose appropriate to each patient is not We then genotyped the CYP2C9 gene for the Japanese so easy because of the large inter-individual variation in common genetic variant, CYP2C9*3 and, based on the dose requirement. We analyzed single nucleotide poly- genotype of these two genes, classified patients into three morphism (SNP) genotypes of the VKORC1 and categories, which we call ‘‘warfarin-responsive index.’’ CYP2C9 genes using DNA from 828 Japanese patients The median warfarin daily dose varied significantly in treated with warfarin, and investigated association be- this classification according to the warfarin-responsive tween SNP genotype and warfarin-maintenance dose. index (2.0 mg/day for index 0 group, 2.5 mg/day for Five SNPs in VKORC1,5¢ flankingÀ1413A>G, intron index 1 group, and 3.5 mg/day for index 2 group; 1À136T>C, intron 2+124C>G, intron 2+837T>C P=4.4·10À13).
    [Show full text]
  • Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid
    Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 231 _____________________________ _____________________________ Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21 BY JOHAN BYLUND ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2000 Dissertation for the Degree of Doctor of Philosophy (Faculty of Pharmacy) in Pharmaceutical Pharmacology presented at Uppsala University in 2000 ABSTRACT Bylund, J. 2000. Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid: Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21. Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from Faculty of Pharmacy 231 50 pp. Uppsala. ISBN 91-554-4784-8. Cytochrome P450 (P450 or CYP) is an enzyme system involved in the oxygenation of a wide range of endogenous compounds as well as foreign chemicals and drugs. This thesis describes investigations of P450-catalyzed oxygenation of prostaglandins, linoleic and arachidonic acids. The formation of bisallylic hydroxy metabolites of linoleic and arachidonic acids was studied with human recombinant P450s and with human liver microsomes. Several P450 enzymes catalyzed the formation of bisallylic hydroxy metabolites. Inhibition studies and stereochemical analysis of metabolites suggest that the enzyme CYP1A2 may contribute to the biosynthesis of bisallylic hydroxy fatty acid metabolites in adult human liver microsomes. 19R-Hydroxy-PGE and 20-hydroxy-PGE are major components of human and ovine semen, respectively. They are formed in the seminal vesicles, but the mechanism of their biosynthesis is unknown. Reverse transcription-polymerase chain reaction using degenerate primers for mammalian CYP4 family genes, revealed expression of two novel P450 genes in human and ovine seminal vesicles.
    [Show full text]
  • Adaptative Evolution of the Vkorc1 Gene in Mus Musculus Domesticus
    Adaptative evolution of the Vkorc1 gene in Mus musculus domesticus is influenced by the selective pressure of anticoagulant rodenticides Joffrey Goulois, Véronique Lambert, Lionel Legros, Etienne Benoit, Virginie Lattard To cite this version: Joffrey Goulois, Véronique Lambert, Lionel Legros, Etienne Benoit, Virginie Lattard. Adaptative evolution of the Vkorc1 gene in Mus musculus domesticus is influenced by the selective pressure of anticoagulant rodenticides. Ecology and Evolution, Wiley Open Access, 2017, 7 (8), pp.2767-2776. 10.1002/ece3.2829. hal-01603961 HAL Id: hal-01603961 https://hal.archives-ouvertes.fr/hal-01603961 Submitted on 26 May 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - ShareAlike| 4.0 International License Received: 27 July 2016 | Revised: 15 January 2017 | Accepted: 28 January 2017 DOI: 10.1002/ece3.2829 ORIGINAL RESEARCH Adaptative evolution of the Vkorc1 gene in Mus musculus domesticus is influenced by the selective pressure of anticoagulant rodenticides Joffrey Goulois1,2 | Véronique Lambert1 | Lionel Legros2 | Etienne Benoit1 | Virginie Lattard1 1USC 1233 RS2GP, VetAgro Sup, INRA, Univ Lyon, F-69280, MARCY L’ETOILE, France Abstract 2Liphatech, Bonnel, Pont du Casse, France Anticoagulant rodenticides are commonly used to control rodent pests worldwide.
    [Show full text]
  • Synonymous Single Nucleotide Polymorphisms in Human Cytochrome
    DMD Fast Forward. Published on February 9, 2009 as doi:10.1124/dmd.108.026047 DMD #26047 TITLE PAGE: A BIOINFORMATICS APPROACH FOR THE PHENOTYPE PREDICTION OF NON- SYNONYMOUS SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN CYTOCHROME P450S LIN-LIN WANG, YONG LI, SHU-FENG ZHOU Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing 100191, P. R. China (LL Wang & Y Li) Discipline of Chinese Medicine, School of Health Sciences, RMIT University, Bundoora, Victoria 3083, Australia (LL Wang & SF Zhou). 1 Copyright 2009 by the American Society for Pharmacology and Experimental Therapeutics. DMD #26047 RUNNING TITLE PAGE: a) Running title: Prediction of phenotype of human CYPs. b) Author for correspondence: A/Prof. Shu-Feng Zhou, MD, PhD Discipline of Chinese Medicine, School of Health Sciences, RMIT University, WHO Collaborating Center for Traditional Medicine, Bundoora, Victoria 3083, Australia. Tel: + 61 3 9925 7794; fax: +61 3 9925 7178. Email: [email protected] c) Number of text pages: 21 Number of tables: 10 Number of figures: 2 Number of references: 40 Number of words in Abstract: 249 Number of words in Introduction: 749 Number of words in Discussion: 1459 d) Non-standard abbreviations: CYP, cytochrome P450; nsSNP, non-synonymous single nucleotide polymorphism. 2 DMD #26047 ABSTRACT Non-synonymous single nucleotide polymorphisms (nsSNPs) in coding regions that can lead to amino acid changes may cause alteration of protein function and account for susceptivity to disease. Identification of deleterious nsSNPs from tolerant nsSNPs is important for characterizing the genetic basis of human disease, assessing individual susceptibility to disease, understanding the pathogenesis of disease, identifying molecular targets for drug treatment and conducting individualized pharmacotherapy.
    [Show full text]
  • Warfarin Sensitivity (CYP2C8, CYP2C9
    Patient Report |FINAL Section 79-1 of New York State Civil Rights Law requires informed consent be obtained from patients (or their legal guardians) prior to pursuing genetic testing. These forms must be kept on file by the ordering physician. Consent forms for genetic testing are available at www.aruplab.com. Incidental findings are not reported unless clinically significant but are available upon request. A Neg result indicates that no variants were detected. All variant alleles are defined based on consensus nomenclature and suggest reduced function of the associated protein(s). CYP2C8 and CYP2C9 are associated with inactivation of warfarin through metabolism. Variant alleles suggest reduced rates of warfarin metabolism, a prolonged time required to achieve steady-state concentrations, and a reduced dose requirement. CYP4F2 is associated with vitamin K recycling. Variant alleles suggest an increased dose requirement. VKORC1 is the therapeutic target for warfarin. Variant alleles suggest increased warfarin sensitivity and a reduced dose requirement. Dosing calculators such as that available through www.WarfarinDosing.org are available to predict loading and therapeutic/maintenance doses. This result has been reviewed and approved by , Ph.D. BACKGROUND INFORMATION: Warfarin Sensitivity (CYP2C8, CYP2C9 , CYP4F2, VKORC1) Genotyping CHARACTERISTICS: Warfarin sensitivity can lead to a life-threatening overdose event such as excessive bleeding. Genetic variation is recognized to explain a large proportion of variability in warfarin dose requirements. This test may predict individual warfarin sensitivity and non-standard dose requirements. The cytochrome P450 (CYP) isozymes 2C8 and 2C9 are involved in the metabolism of many drugs. Variants in the genes that code for CYP2C8 and CYP2C9 may influence pharmacokinetics of substrates such as warfarin, and may predict or explain non-standard dose requirements, therapeutic failure or adverse reactions.
    [Show full text]
  • Positive Selection in the Chromosome 16 VKORC1 Genomic Region Has Contributed to the Variability of Anticoagulant Response in Humans
    Positive Selection in the Chromosome 16 VKORC1 Genomic Region Has Contributed to the Variability of Anticoagulant Response in Humans Blandine Patillon1,2*., Pierre Luisi3.,He´le`ne Blanche´ 4, Etienne Patin5, Howard M. Cann4, Emmanuelle Ge´nin1", Audrey Sabbagh6" 1 Inserm UMRS-946, Genetic Variability and Human Diseases, Institut Universitaire d’He´matologie, Universite´ Paris Diderot, Paris, France, 2 Universite´ Paris Sud, Kremlin- Biceˆtre, France, 3 Institute of Evolutionary Biology, CEXS-UPF-PRBB, Catalonia, Barcelona, Spain, 4 Fondation Jean-Dausset-CEPH, Paris, France, 5 Human Evolutionary Genetics, CNRS URA3012, Institut Pasteur, Paris, France, 6 UMR IRD 216, Universite´ Paris Descartes, Paris, France Abstract VKORC1 (vitamin K epoxide reductase complex subunit 1, 16p11.2) is the main genetic determinant of human response to oral anticoagulants of antivitamin K type (AVK). This gene was recently suggested to be a putative target of positive selection in East Asian populations. In this study, we genotyped the HGDP-CEPH Panel for six VKORC1 SNPs and downloaded chromosome 16 genotypes from the HGDP-CEPH database in order to characterize the geographic distribution of footprints of positive selection within and around this locus. A unique VKORC1 haplotype carrying the promoter mutation associated with AVK sensitivity showed especially high frequencies in all the 17 HGDP-CEPH East Asian population samples. VKORC1 and 24 neighboring genes were found to lie in a 505 kb region of strong linkage disequilibrium in these populations. Patterns of allele frequency differentiation and haplotype structure suggest that this genomic region has been submitted to a near complete selective sweep in all East Asian populations and only in this geographic area.
    [Show full text]
  • Supplementary Tables, Figures and Other Documents
    Clinical Relevance of a 16-Gene Pharmacogenetic Panel Test for Medication Management in a Cohort of 135 Patients David Niedrig1,2, Ali Rahmany1,3, Kai Heib4, Karl-Dietrich Hatz4, Katja Ludin5, Andrea M. Burden3, Markus Béchir6, Andreas Serra7, Stefan Russmann1,3,7,* 1 drugsafety.ch; Zurich, Switzerland 2 Hospital Pharmacy, Clinic Hirslanden Zurich; Zurich Switzerland 3 Swiss Federal Institute of Technology Zurich (ETHZ); Zurich, Switzerland 4 INTLAB AG; Uetikon am See, Switzerland 5 Labor Risch, Molecular Genetics; Berne, Switzerland 6 Center for Internal Medicine, Clinic Hirslanden Aarau; Aarau, Switzerland 7 Institute of Internal Medicine and Nephrology, Clinic Hirslanden Zurich; Zurich, Switzerland * Correspondence: [email protected]; Tel.: +41 (0)44 221 1003 Supplementary Tables, Figures and Other Documents Figure S1: Example of credit-card sized pharmacogenomic profile issued to patients 1 Table S2: SNPs analyzed by the 16-gene panel test Gene Allele rs number ABCB1 Haplotypes 1236-2677- rs1045642 ABCB1 3435 rs1128503 ABCB1 rs2032582 COMT Haplotypes 6269-4633- rs4633 COMT 4818-4680 rs4680 COMT rs4818 COMT rs6269 CYP1A2 *1C rs2069514 CYP1A2 *1F rs762551 CYP1A2 *1K rs12720461 CYP1A2 *7 rs56107638 CYP1A2 *11 rs72547513 CYP2B6 *6 rs3745274 CYP2B6 *18 rs28399499 CYP2C19 *2 rs4244285 CYP2C19 *3 rs4986893 CYP2C19 *4 rs28399504 CYP2C19 *5 rs56337013 CYP2C19 *6 rs72552267 CYP2C19 *7 rs72558186 CYP2C19 *8 rs41291556 CYP2C19 *17 rs12248560 CYP2C9 *2 rs1799853 CYP2C9 *3 rs1057910 CYP2C9 *4 rs56165452 CYP2C9 *5 rs28371686 CYP2C9 *6 rs9332131 CYP2C9
    [Show full text]
  • Clinical Implications of 20-Hydroxyeicosatetraenoic Acid in the Kidney, Liver, Lung and Brain
    1 Review 2 Clinical Implications of 20-Hydroxyeicosatetraenoic 3 Acid in the Kidney, Liver, Lung and Brain: An 4 Emerging Therapeutic Target 5 Osama H. Elshenawy 1, Sherif M. Shoieb 1, Anwar Mohamed 1,2 and Ayman O.S. El-Kadi 1,* 6 1 Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton T6G 2E1, AB, Canada; 7 [email protected] (O.H.E.); [email protected] (S.M.S.); [email protected] (A.M.) 8 2 Department of Basic Medical Sciences, College of Medicine, Mohammed Bin Rashid University of 9 Medicine and Health Sciences, Dubai, United Arab Emirates 10 * Correspondence: [email protected]; Tel.: 780-492-3071; Fax: 780-492-1217 11 Academic Editor: Kishor M. Wasan 12 Received: 12 January 2017; Accepted: 15 February 2017; Published: 20 February 2017 13 Abstract: Cytochrome P450-mediated metabolism of arachidonic acid (AA) is an important 14 pathway for the formation of eicosanoids. The ω-hydroxylation of AA generates significant levels 15 of 20-hydroxyeicosatetraenoic acid (20-HETE) in various tissues. In the current review, we discussed 16 the role of 20-HETE in the kidney, liver, lung, and brain during physiological and 17 pathophysiological states. Moreover, we discussed the role of 20-HETE in tumor formation, 18 metabolic syndrome and diabetes. In the kidney, 20-HETE is involved in modulation of 19 preglomerular vascular tone and tubular ion transport. Furthermore, 20-HETE is involved in renal 20 ischemia/reperfusion (I/R) injury and polycystic kidney diseases. The role of 20-HETE in the liver is 21 not clearly understood although it represents 50%–75% of liver CYP-dependent AA metabolism, 22 and it is associated with liver cirrhotic ascites.
    [Show full text]
  • Prevalence​Of​VKORC1​Single​Nucleotide​Polymorphism​(SNP)
    113 Original​Article Prevalence​of​VKORC1​Single​Nucleotide​Polymorphism​(SNP)​–​1639​ in​Thai​Adult​Patients​Who​Have​INR​More​Than​4​from​Warfarin Rawisut​Deoisares​and​Ponlapat​Rojnuckarin Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital Abstract : Background : Previous studies showed that VKORC1 -1639 SNP genotype AA was more common in Asian compared with Caucasian population and associated with lower warfarin dose requirement. We hypothesized that this genetically-determined warfarin sensitivity may predispose the patients with this genotype to warfarin overdosage. Method : A descriptive study was conducted in adult patients taking warfarin with INR more than 4 at King Chulalongkorn Memorial Hospital. The VKORC1 -1639 genotyping in these cases was performed. Results : There were a total of 44 cases of warfarin overdose. The median age was 66 yr, range 21-90 yr, and 15 patients (34%) were male. The numbers (%) of VKORC1 -1639 genotype AA, AG and GG were 26 (59.1%), 16 (36.4%) and 2 (4.5%), respectively. This prevalence was similar to general Thai population and thromboembolic patients receiving warfarin. Conclusion : Our result implies that VKORC1 -1639 polymorphism is not a strong risk factor for warfarin overdose. Key Words : l Warfarin l Overdosage l VKORC1 l Single nucleotide polymorphism J Hematol Transfus Med 2010;20:113-8. Introduction Vitamin K is the cofactor of hepatic gamma carboxylation. Since 1954, warfain has been used worldwide as an After the reaction, vitamin K is transformed into an anticoagulant for treatment or prophylaxis of venous oxidized from that is inactive. VKORC1 can reduce the thromboembolism.1 Warfarin has good oral bioavailability.
    [Show full text]
  • Effect of Genetic Variability in the CYP4F2, CYP4F11 and CYP4F12 Genes on Liver Mrna Levels and Warfarin Response
    Effect of genetic variability in the CYP4F2, CYP4F11 and CYP4F12 genes on liver mRNA levels and warfarin response J. Eunice Zhang1, Kathrin Klein2, Andrea L. Jorgensen3, Ben Francis3, Ana Alfirevic1, Stephane Bourgeois4, Panagiotis Deloukas4,5,6, Ulrich M. Zanger2 and Munir Pirmohamed1* 1Wolfson Centre for Personalized Medicine, Department of Molecular & Clinical Pharmacology, The University of Liverpool, UK 2Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tuebingen, Tuebingen, Germany. 3Department of Biostatistics, The University of Liverpool, UK 4William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK 5Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK. 6Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders, King Abdulaziz University, Jeddah, Saudi Arabia. Correspondence: Professor Sir Munir Pirmohamed Wolfson Centre for Personalised Medicine Department of Molecular & Clinical Pharmacology Block A: Waterhouse Buildings The University of Liverpool 1-5 Brownlow Street L69 3GL, UK [email protected] Running Title: Genotype-phenotype assessment of CYP4F12-CYP4F2-CYP4F11 region Keywords: warfarin, pharmacogenetics, mRNA expression, CYP4F2, CYP4F11, CYP4F12 1 Abstract Genetic polymorphisms in the gene encoding cytochrome P450 (CYP) 4F2, a vitamin K oxidase, affect stable warfarin dose requirements and time to therapeutic INR. CYP4F2 is part of the CYP4F gene cluster, which is highly polymorphic and exhibits a high degree of linkage disequilibrium, making it difficult to define causal variants. Our objective was to examine the effect of genetic variability in the CYP4F gene cluster on expression of the individual CYP4F genes and warfarin response. mRNA levels of the CYP4F gene cluster were quantified in human liver samples (n=149) obtained from a well characterized liver bank and fine mapping of the CYP4F gene cluster encompassing CYP4F2, CYP4F11 and CYP4F12 was performed.
    [Show full text]
  • Vitamin K Epoxide Recycling Polypeptide Vkorc1, a Therapeutic
    (19) TZZ __T (11) EP 2 272 951 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 9/04 (2006.01) C12N 15/52 (2006.01) 23.07.2014 Bulletin 2014/30 C07K 16/40 (2006.01) G01N 33/50 (2006.01) A01K 67/027 (2006.01) C12N 5/10 (2006.01) (21) Application number: 10011278.8 (22) Date of filing: 12.10.2004 (54) Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives VKCORC1 (vitamin k epoxide recycling polypeptide), ein therapeutisches Ziel für Coumarin und deren Derivate Polypeptide VKCORC1 de recyclage de la vitamine k- epoxide, cible thérapeutique de la coumarine et de ses dérivés (84) Designated Contracting States: (74) Representative: HOFFMANN EITLE AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Patent- und Rechtsanwälte HU IE IT LI LU MC NL PL PT RO SE SI SK TR Arabellastrasse 4 81925 München (DE) (30) Priority: 14.10.2003 US 511041 P (56) References cited: (43) Date of publication of application: EP-A1- 2 189 523 WO-A-00/03015 12.01.2011 Bulletin 2011/02 WO-A2-2005/030039 (62) Document number(s) of the earlier application(s) in • ROST SIMONE ET AL: "Mutations in VKORC1 accordance with Art. 76 EPC: cause warfarin resistance and multiple 10002316.7 / 2 189 523 coagulation factor deficiency type 2.", NATURE. 04790318.2 / 1 673 450 5 FEB 2004, vol. 427, no. 6974, 5 February 2004 (2004-02-05), pages537-541, XP002318816, ISSN: (73) Proprietors: 1476-4687 • Baxter International Inc.
    [Show full text]
  • Screening 20-Hete Inhibitors in Microsomal Incubates
    SCREENING 20-HETE INHIBITORS IN MICROSOMAL INCUBATES USING UPLC-MS/MS by Chenxiao Tang Bachelor of Science, Capital Medical University, 2014 Submitted to the Graduate Faculty of School of Pharmacy in partial fulfillment of the requirements for the degree of Master of Science University of Pittsburgh 2016 Copyright © by Chenxiao Tang 2016 ii SCREENING 20-HETE INHIBITORS IN MICROSOMAL INCUBATES USING UPLC-MS/MS Chenxiao Tang, B.S. University of Pittsburgh, 2016 20-hydroxyeicosatetraenoic acid (20-HETE) is a metabolite of arachidonic acid (AA) formed by cytochrome P450 (CYP) 4A11 and CYP4F2 in humans, with potent microvascular constriction activity. Inhibition of 20-HETE formation is neuroprotective in subarachnoid hemorrhage, cardiac arrest and thromboembolic stroke preclinical models. These findings suggest that inhibition of 20-HETE formation is a potential therapeutic strategy for neuroprotection after brain injury. At this point, a clinically relevant 20-HETE inhibitor is not available to be evaluated as a therapeutic intervention. Our goal is to identify a selective, metabolically stable, and potent 20-HETE inhibitor. Test compounds were obtained either via virtual screening against a CYP4F2 homology model or from scaffold hopping from structures of known inhibitors. Four different types of microsomes including human liver microsome (HLM), recombinant CYP4F2 (rCYP4F2), rat liver microsome (RLM) and rat kidney microsome (RKM) were used. AA was incubated in microsomes with/without compound for 20 min. 20-HETE formation rate was quantified using a validated UPLC-MS/MS assay and normalized by vehicle control group. Other eicosanoids including 15-, 12-HETEs, epoxyeicosatrienoic acids (EETs), iii and dihydroxyeicosatrienoic acids (DiHETs) were monitored simultaneously.
    [Show full text]